Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014749790> ?p ?o ?g. }
- W2014749790 endingPage "243" @default.
- W2014749790 startingPage "226" @default.
- W2014749790 abstract "Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) and gemcitabine (dFdC), are widely used in chemotherapy regimes for colorectal, breast, head and neck, non-small-cell lung cancer, pancreatic cancer and leukaemias. Extensive metabolism is a prerequisite for conversion of these pyrimidine prodrugs into active compounds. Interindividual variation in the activity of metabolising enzymes can affect the extent of prodrug activation and, as a result, act on the efficacy of chemotherapy treatment. Genetic factors at least partly explain interindividual variation in antitumour efficacy and toxicity of pyrimidine antagonists. In this review, proteins relevant for the efficacy and toxicity of pyrimidine antagonists will be summarised. In addition, the role of germline polymorphisms, tumour-specific somatic mutations and protein expression levels in the metabolic pathways and clinical pharmacology of these drugs are described. Germline polymorphisms of uridine monophosphate kinase (UMPK), orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and methylene tetrahydrofolate reductase (MTHFR) and gene expression levels of OPRT, UMPK, TS, DPD, uridine phosphorylase, uridine kinase, thymidine phosphorylase, thymidine kinase, deoxyuridine triphosphate nucleotide hydrolase are discussed in relation to 5-FU efficacy. Cytidine deaminase (CDD) and 5'-nucleotidase (5NT) gene polymorphisms and CDD, 5NT, deoxycytidine kinase and MRP5 gene expression levels and their potential relation to dFdC and ara-C cytotoxicity are reviewed." @default.
- W2014749790 created "2016-06-24" @default.
- W2014749790 creator A5010848198 @default.
- W2014749790 creator A5014311522 @default.
- W2014749790 creator A5016301942 @default.
- W2014749790 creator A5065829795 @default.
- W2014749790 creator A5086412405 @default.
- W2014749790 date "2005-07-25" @default.
- W2014749790 modified "2023-09-27" @default.
- W2014749790 title "Genetic factors influencing Pyrimidine-antagonist chemotherapy" @default.
- W2014749790 cites W1484628085 @default.
- W2014749790 cites W1498281658 @default.
- W2014749790 cites W1688941817 @default.
- W2014749790 cites W1742102714 @default.
- W2014749790 cites W1751651908 @default.
- W2014749790 cites W1768019140 @default.
- W2014749790 cites W1771671972 @default.
- W2014749790 cites W1797303364 @default.
- W2014749790 cites W1802949207 @default.
- W2014749790 cites W1828890888 @default.
- W2014749790 cites W1844681537 @default.
- W2014749790 cites W1860986539 @default.
- W2014749790 cites W1912423223 @default.
- W2014749790 cites W1939106203 @default.
- W2014749790 cites W1963757710 @default.
- W2014749790 cites W1966251853 @default.
- W2014749790 cites W1966603374 @default.
- W2014749790 cites W1968082032 @default.
- W2014749790 cites W1968328035 @default.
- W2014749790 cites W1971683915 @default.
- W2014749790 cites W1972770199 @default.
- W2014749790 cites W1972823987 @default.
- W2014749790 cites W1974161664 @default.
- W2014749790 cites W1974957356 @default.
- W2014749790 cites W1977607540 @default.
- W2014749790 cites W1977850226 @default.
- W2014749790 cites W1978026907 @default.
- W2014749790 cites W1979788220 @default.
- W2014749790 cites W1980735579 @default.
- W2014749790 cites W1981559468 @default.
- W2014749790 cites W1986661546 @default.
- W2014749790 cites W1987098890 @default.
- W2014749790 cites W1987207125 @default.
- W2014749790 cites W1987390316 @default.
- W2014749790 cites W1991689414 @default.
- W2014749790 cites W1995336792 @default.
- W2014749790 cites W1995709107 @default.
- W2014749790 cites W1998204369 @default.
- W2014749790 cites W2003306235 @default.
- W2014749790 cites W2004072274 @default.
- W2014749790 cites W2007442696 @default.
- W2014749790 cites W2009085422 @default.
- W2014749790 cites W2011189845 @default.
- W2014749790 cites W2012151258 @default.
- W2014749790 cites W2013784882 @default.
- W2014749790 cites W2014062936 @default.
- W2014749790 cites W2015310536 @default.
- W2014749790 cites W2015430600 @default.
- W2014749790 cites W2019847722 @default.
- W2014749790 cites W2020058335 @default.
- W2014749790 cites W2026363946 @default.
- W2014749790 cites W2027945188 @default.
- W2014749790 cites W2029515374 @default.
- W2014749790 cites W2030748852 @default.
- W2014749790 cites W2032480351 @default.
- W2014749790 cites W2032500323 @default.
- W2014749790 cites W2038033520 @default.
- W2014749790 cites W2038811395 @default.
- W2014749790 cites W2041418605 @default.
- W2014749790 cites W2047600749 @default.
- W2014749790 cites W2047873654 @default.
- W2014749790 cites W2048231138 @default.
- W2014749790 cites W2051676872 @default.
- W2014749790 cites W2051836198 @default.
- W2014749790 cites W2052255167 @default.
- W2014749790 cites W2052897463 @default.
- W2014749790 cites W2053335596 @default.
- W2014749790 cites W2059701501 @default.
- W2014749790 cites W2060571444 @default.
- W2014749790 cites W2062790845 @default.
- W2014749790 cites W2065915399 @default.
- W2014749790 cites W2068907962 @default.
- W2014749790 cites W2076435358 @default.
- W2014749790 cites W2078000955 @default.
- W2014749790 cites W2082275089 @default.
- W2014749790 cites W2086299451 @default.
- W2014749790 cites W2086834400 @default.
- W2014749790 cites W2087764275 @default.
- W2014749790 cites W2089024911 @default.
- W2014749790 cites W2093716292 @default.
- W2014749790 cites W2095807734 @default.
- W2014749790 cites W2097212313 @default.
- W2014749790 cites W2100021150 @default.
- W2014749790 cites W2104909346 @default.
- W2014749790 cites W2105008483 @default.
- W2014749790 cites W2105293285 @default.
- W2014749790 cites W2111031501 @default.
- W2014749790 cites W2111974906 @default.